MA38425B1 - Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 - Google Patents

Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Info

Publication number
MA38425B1
MA38425B1 MA38425A MA38425A MA38425B1 MA 38425 B1 MA38425 B1 MA 38425B1 MA 38425 A MA38425 A MA 38425A MA 38425 A MA38425 A MA 38425A MA 38425 B1 MA38425 B1 MA 38425B1
Authority
MA
Morocco
Prior art keywords
compounds
selective agonists
receptor
bicyclic compounds
diseases
Prior art date
Application number
MA38425A
Other languages
English (en)
Other versions
MA38425A1 (fr
Inventor
Marta Dabros
T G Murali Dhar
Hai-Yun Xiao
Alaric J Dyckman
Eric J Chan
Daniel Richard Roberts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA38425A1 publication Critical patent/MA38425A1/fr
Publication of MA38425B1 publication Critical patent/MA38425B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i) et/ou un de leurs sels; dans laquelle r représente -oh ou -op(o)(oh)2. L'invention concerne également des méthodes d'utilisation de tels composés comme agonistes sélectifs pour le récepteur s1p1couplé à la protéine g, et des compositions pharmaceutiques comprenant de tels composés. Ces composés sont utiles dans le traitement, la prévention, ou le ralentissement de la progression de maladies ou de troubles dans des domaines thérapeutiques variés, tels que ceux des maladies auto-immunes et des maladies vasculaires.
MA38425A 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 MA38425B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (fr) 2013-02-21 2014-02-21 Composés bicycliques

Publications (2)

Publication Number Publication Date
MA38425A1 MA38425A1 (fr) 2017-12-29
MA38425B1 true MA38425B1 (fr) 2019-03-29

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38425A MA38425B1 (fr) 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Country Status (35)

Country Link
US (3) US9115054B2 (fr)
EP (1) EP2958888B1 (fr)
JP (1) JP6277210B2 (fr)
KR (1) KR102242265B1 (fr)
CN (1) CN105026362B (fr)
AR (1) AR094851A1 (fr)
AU (1) AU2014218883B2 (fr)
BR (1) BR112015019919A2 (fr)
CA (1) CA2902168C (fr)
CL (1) CL2015002358A1 (fr)
CY (1) CY1118641T1 (fr)
DK (1) DK2958888T3 (fr)
EA (1) EA025294B1 (fr)
ES (1) ES2613262T3 (fr)
HK (1) HK1218111A1 (fr)
HR (1) HRP20170247T1 (fr)
HU (1) HUE031626T2 (fr)
IL (1) IL240613B (fr)
LT (1) LT2958888T (fr)
MA (1) MA38425B1 (fr)
MX (1) MX2015010347A (fr)
MY (1) MY173990A (fr)
PE (1) PE20151746A1 (fr)
PH (1) PH12015501793A1 (fr)
PL (1) PL2958888T3 (fr)
PT (1) PT2958888T (fr)
RS (1) RS55703B1 (fr)
SG (1) SG11201506408TA (fr)
SI (1) SI2958888T1 (fr)
SM (1) SMT201700115B (fr)
TN (1) TN2015000356A1 (fr)
TW (1) TWI613182B (fr)
UY (1) UY35338A (fr)
WO (1) WO2014130752A2 (fr)
ZA (1) ZA201506965B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009731A2 (fr) 2013-07-15 2015-01-22 The Regents Of The University Of California Analogues azacycliques de fty720 à structure contrainte
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
WO2017053990A1 (fr) * 2015-09-24 2017-03-30 The Regents Of The University Of California Molécules de type sphingolipide synthétiques, médicaments, procédés pour leur synthèse et procédés de traitement
US10633354B2 (en) 2016-09-02 2020-04-28 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032631A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'éther d'oxime
WO2019032632A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'alkylphényle
WO2021062168A1 (fr) * 2019-09-25 2021-04-01 The Regents Of The University Of California Molécules inspirees par des sphingolipides synthetiques ayant des groupes pendants heteroaromatiques cytotoxiques, leurs procédés de synthèse et méthodes de traitement

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
EP1470137B1 (fr) 2002-01-18 2009-09-02 Merck & Co., Inc. Agonistes du recepteur edg
US7351725B2 (en) 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
US7309721B2 (en) 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
US7199142B2 (en) 2002-06-17 2007-04-03 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006047195A2 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
BRPI0607156A2 (pt) 2005-02-18 2009-08-11 Innodia Inc composto, composição farmacêutica, uso do composto, kit farmacêutico, método para estimular a absorção de glicose por células de músculo e/ou célula de adipócito e método para estimular a secreção pancreática
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
JPWO2006115188A1 (ja) 2005-04-22 2008-12-18 第一三共株式会社 ヘテロ環化合物
CA2610310A1 (fr) 2005-06-08 2006-12-14 Novartis Ag Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
CA2619101A1 (fr) 2005-08-23 2007-03-01 Irm Llc Composes immunosuppresseurs et compositions associees
RU2430913C2 (ru) 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
KR20080086546A (ko) 2006-01-27 2008-09-25 유니버시티 오브 버지니아 페이턴트 파운데이션 신경병증성 통증의 치료 방법
WO2007088450A2 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagoniste du récepteur h-3
WO2007109330A2 (fr) 2006-03-21 2007-09-27 Epix Delaware, Inc. Composés modulant le récepteur de la sip
JP2009530381A (ja) 2006-03-23 2009-08-27 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、この化合物を含む組成物及び使用方法
EP2003132B1 (fr) 2006-04-03 2014-03-05 Astellas Pharma Inc. Dérivés d'oxadiazole en tant qu'agonistes du S1P1
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
EP2069335B1 (fr) 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
RU2009128062A (ru) * 2006-12-21 2011-01-27 Эбботт Лэборетриз (Us) Соединения агонисты и антагонисты рецептора сфингозин-1-фосфата
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
JP5248528B2 (ja) 2007-02-02 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
WO2009057079A2 (fr) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Nouveaux dérivés de pyrimidine
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
ES2431354T3 (es) 2008-04-01 2013-11-26 Theravance, Inc. Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu
WO2010042998A1 (fr) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd Modulateurs des récepteurs s1p
KR20110100624A (ko) 2008-12-18 2011-09-14 메르크 세로노 에스. 에이. 다발성 경화증의 치료에 유용한 옥사디아졸 융합된 헤테로사이클릭 유도체
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
EP2389377B1 (fr) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
WO2010085581A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
EP2382211B1 (fr) 2009-01-23 2012-12-19 Bristol-Myers Squibb Company Dérivés de pyrazole-1,2,4-oxadiazole en tant qu'agonistes de sphingosine-1-phosphate
JP2012517445A (ja) 2009-02-10 2012-08-02 アボット・ラボラトリーズ Ｓ１ｐ受容体アゴニストおよびアンタゴニストを調製するための方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP5728487B2 (ja) 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
WO2011133734A1 (fr) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company Amides d'acide 4-(5-isoxazolyl ou 5-pyrazolyl-1,2,4-oxadiazol-3-yl)-mandélique comme agonistes du récepteur de la sphingosine-1-phosphate de type 1
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2012012477A1 (fr) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Composés 3-phényl-1,2,4-oxadiazole substitués
CN103237795B (zh) 2010-09-24 2015-10-21 百时美施贵宝公司 经取代的噁二唑化合物及其作为s1p1激动剂的用途
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
EP2541155B1 (fr) 2011-04-26 2016-02-24 Panasonic Intellectual Property Management Co., Ltd. Système de chauffage, et procédé de commande de système de chauffage
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
CN104684560B (zh) 2012-07-27 2018-08-17 比奥根艾迪克Ma公司 作为s1p调节剂和/或atx调节剂的化合物

Also Published As

Publication number Publication date
JP2016513124A (ja) 2016-05-12
JP6277210B2 (ja) 2018-02-07
TW201444786A (zh) 2014-12-01
ZA201506965B (en) 2017-08-30
CA2902168A1 (fr) 2014-08-28
WO2014130752A2 (fr) 2014-08-28
PL2958888T3 (pl) 2017-07-31
US20160251309A1 (en) 2016-09-01
CN105026362B (zh) 2017-07-14
US9359286B2 (en) 2016-06-07
EA025294B1 (ru) 2016-12-30
KR20150119352A (ko) 2015-10-23
CY1118641T1 (el) 2017-07-12
MX2015010347A (es) 2015-11-16
SG11201506408TA (en) 2015-09-29
AU2014218883B2 (en) 2017-05-11
HK1218111A1 (zh) 2017-02-03
HRP20170247T1 (hr) 2017-04-07
SMT201700115B (it) 2017-03-08
IL240613B (en) 2018-06-28
ES2613262T3 (es) 2017-05-23
LT2958888T (lt) 2017-02-10
SI2958888T1 (sl) 2017-01-31
WO2014130752A3 (fr) 2014-10-23
UY35338A (es) 2014-08-29
EA201591409A1 (ru) 2015-12-30
KR102242265B1 (ko) 2021-04-19
RS55703B1 (sr) 2017-07-31
AU2014218883A1 (en) 2015-10-15
EP2958888A2 (fr) 2015-12-30
TWI613182B (zh) 2018-02-01
PH12015501793B1 (en) 2015-11-09
PE20151746A1 (es) 2015-12-02
MY173990A (en) 2020-03-03
US20150315128A1 (en) 2015-11-05
PH12015501793A1 (en) 2015-11-09
TN2015000356A1 (en) 2017-01-03
CN105026362A (zh) 2015-11-04
CL2015002358A1 (es) 2016-02-26
IL240613A0 (en) 2015-10-29
PT2958888T (pt) 2017-02-03
HUE031626T2 (en) 2017-07-28
US9487481B2 (en) 2016-11-08
DK2958888T3 (en) 2017-03-06
MA38425A1 (fr) 2017-12-29
BR112015019919A2 (pt) 2017-07-18
AR094851A1 (es) 2015-09-02
US9115054B2 (en) 2015-08-25
US20140235591A1 (en) 2014-08-21
CA2902168C (fr) 2019-01-08
EP2958888B1 (fr) 2016-11-23

Similar Documents

Publication Publication Date Title
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40290A1 (fr) Agents immunorégulateurs
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA37929A1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
TN2014000371A1 (fr) Dérivés macrocycliques pour le traitement de maladies prolifératives